Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data
H.C. Wainwright analyst Arthur He raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares. The company this morning announced positive results from the induction period of its ongoing Phase 2b REZOLVE-AD study evaluating rezpegaldesleukin in patients with moderate to-severe atopic dermatitis, the analyst tells investors in a research note. Citing the drug’s “highly differentiated mechanism of action” compared to currently approved therapies, H.C. Wainwright believes rezpeg “has the potential to reshape the treatment landscape” for atopic dermatitis. The firm expects to see further improvement in efficacy in the next clinical data update when the 36-week maintenance data is expected to be reported in Q1 of 2026. Nektar says a “paradigm-shifting” atopic dermatitis drug “has arrived.” The stock in midday trading is up 134%, or $12.82, to $22.36.
Confident Investing Starts Here:
-
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
-
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas" href="https://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">Try Now>>
Read More on NKTR:
Latest News
- Consumer Confidence Worsened in June, Survey Shows
- Perma-Pipe Stock Jumps Into the Top 100 Stocks to Buy: Does This Small Cap Have What It Takes to Become a Mid Cap?
- Should You Buy Amrize Stock Now After the AMRZ Spinoff?
- Survey Shows U.S. Consumer Confidence Worsened in June
- Berkshire Hathaway Has Declined Over 10% Since Warren Buffett Announced His Retirement. Is the Stock a Buy?
- Analyst Report: Fortive Corp
